Japanese drugmaker Eisai said cognitive function slowed over 18 months in patients who received the drug, called lecanemab.
BSIP / UIG via Getty ImagesThe Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness.
Dr. Alberto Espay, a neurologist at the University of Cincinnati College of Medicine, said that the benefit was"small" and that it fell below the threshold of what would be meaningful to a patient. Still, he said,"patients can view this with cautious optimism."
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Leer más »
Alzheimer’s Drug Slows Disease Progression in TrialEisai and Biogen said their experimental Alzheimer’s drug significantly slowed progression of the memory-robbing disease in a large study, bolstering the drug’s prospects of approval.
Leer más »
Jury begins deliberations in Graham Weston’s divorce trial without hearing closing arguments from wifeElizabeth Weston, who is representing herself, called the proceedings a “show trial.”
Leer más »
Jurors return verdict in favor of Graham Weston, court still hearing arguments on division of assetsWhen the judge finished reading the jury’s verdict, Elizabeth Weston moved for a mistrial. Just as he had done with previous mistrial requests, the judge denied it.
Leer más »